Evidence map›Paper›PMID 35372704›Full record

ArticlePhysics and imaging in radiation oncology2022

Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery.

Biche Osong, Carlotta Masciocchi, Andrea Damiani, Inigo Bermejo, Elisa Meldolesi, Giuditta Chiloiro, Maaike Berbee, Seok Ho Lee, Andre Dekker, Vincenzo Valentini and 11 more

Open access · goldAbstract read
In one paragraph

Article in Physics and imaging in radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 10 countries.

Biche OsongDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Carlotta MasciocchiFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Andrea DamianiUniversita Cattolica del Sacro Cuore, Roma, Italy.
Inigo BermejoDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Elisa MeldolesiFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Giuditta ChiloiroFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Maaike BerbeeDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Seok Ho LeeDepartment of Radiation Oncology, Gachon University, College of Medicine, Gil Medical Center, Incheon, South Korea.
Andre DekkerDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Vincenzo ValentiniFondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia.
Jean-Pierre GerardDepartment of Radiotherapy, Centre Antoine-Lacassagne, Nice, France.
Claus RödelDepartment of Radiotherapy, University of Frankfurt, Germany.
Krzysztof BujkoDepartment of Radiotherapy I, M. Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Cornelis van de VeldeDepartment of Surgery, Leiden University Medical Center, The Netherlands.
Joakim FolkessonDepartment of Surgery, Uppsala University Hospital, Uppsala, Sweden.
Aldo SainatoDepartment of Radiotherapy, Pisa University, Italy.
Robert Glynne-JonesDepartment of Radiotherapy, Mount Vernon Cancer Centre, Northwood, United Kingdom.
Samuel NganDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Morten BrændengenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
David Sebag-MontefioreLeeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
Johan van SoestDepartment of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Agostino Gemelli University Polyclinic · ITMaastricht University · NLMaastro Clinic · NLUniversità Cattolica del Sacro Cuore · ITCentre Antoine Lacassagne · FRGachon University Gil Medical Center · KRGoethe University Frankfurt · DELeiden University Medical Center · NLMount Vernon Cancer Centre · GBOslo University Hospital · NOPeter MacCallum Cancer Centre · AUThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversity of Leeds · GBUniversity of Pisa · ITUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Tumor recurrence, a characteristic of malignant tumors, is the biggest concern for rectal cancer survivors. The epidemiology of the disease calls for a pressing need to improve healthcare quality and patient outcomes. Prediction models such as Bayesian networks, which can probabilistically reason under uncertainty, could assist caregivers with patient management. However, some concerns are associated with the standard approaches to developing these structures in medicine. Therefore, this study aims to compare Bayesian network structures that stem from these two techniques. Patients and Methods: A retrospective analysis was performed on 6754 locally advanced rectal cancer (LARC) patients enrolled in 14 international clinical trials. Local tumor recurrence at 2, 3, and 5-years was defined as the endpoints of interest. Five rectal cancer treating physicians from three countries elicited the expert structure. The algorithmic structure was inferred from the data with the hill-climbing algorithm. Structural performance was assessed with calibration plots and area under the curve values. Results: The area under the curve for the expert structure on the training and validation data was above 0.9 and 0.8, respectively, for all the time points. However, the algorithmic structure had superior predictive performance over the expert structure for all time points of interest. Conclusion: We have developed and internally validated a Bayesian networks structure from experts' opinions, which can predict the risk of a LARC patient developing a tumor recurrence at 2, 3, and 5 years. Our result shows that the algorithmic-based structures are more performant and less interpretable than expert-based structures.

Identifiers

PMID35372704
PMCPMC8968052
OpenAlexW4221105300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.